anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine, specifically an adhesive material for gluing to skin, etc. which maintains proper adherence during a certain period of time after adhered on skin surface thereby preventing tearing it off easily or causing skin irritation; and when it is supposed to be torn off from skin surface after termination of required period of time, allows tearing if off easily without causing pain or physical skin irritation, and an adhesive sticky preparation containing the adhesive material and percutaneously absorbed medicinal agent in an adhesive layer. Besides, the invention concerns the adhesive material that contains a substrate and the adhesive layer laminated on one surface of the substrate where the adhesive layer has the apparent viscosity 0.2ù104 to 10ù104 Pa ù s at 30C and contains two types of synthetic rubber of various fluidity. ^ EFFECT: invention does not irritate skin. ^ 15 cl, 6 tbl, 3 ex
In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. We uses a contact-force catheter. Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of 400 at the posterior wall/roof an 550 at the anterior wall are reached.
This group will include 101 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation .
PCT No. PCT/SE94/00917 Sec. 371 Date Aug. 26, 1996 Sec. 102(e) Date Aug. 26, 1996 PCT Filed Oct. 3, 1994 PCT Pub. No. WO95/12399 PCT Pub. Date May 11, 1995A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. The starch microspheres are preferably degradable epichlorhydrin cross-linked starch microspheres. The average diameter of the microspheres is from around 1  mu m to around 200  mu m, preferably around 45  mu m. The invention also encompasses a method for manufacturing a powdery pharmaceutical composition comprising nicotine and starch microspheres. The invention further comprises a method of diminishing the desire of a subject to use tobacco which comprises the step of administering to the subject the above powdery pharmaceutical composition.
OBJECTIVES: To assess the impact of urinary incontinence (UI) on health outcomes over the entire spectrum of acute stroke severity (National Institutes of Health Stroke Scale [NIHSS] scores: 0-42), due to a paucity of data on patients with milder strokes.
PATIENTS AND METHODS: Data were prospectively collected (2014-2016) from the Sentinel Stroke National Audit Programme (1593 men, 1591 women; mean [SD] age 76.8 [13.3] years) admitted to four UK hyperacute stroke units (HASUs). Relationships between variables were assessed by multivariable logistic regression. Data were adjusted for age, sex, comorbidities, pre-stroke disability and intra-cranial haemorrhage, and presented as odds ratios with 95% confidence intervals.
RESULTS: Amongst patients with no symptoms or a minor stroke (NIHSS scores of 0-4), compared to patients without UI, patients with UI had significantly greater risks of poor outcomes including: in-hospital mortality; disability at discharge; in-hospital pneumonia; urinary tract infection within 7 days of admission; prolonged length of stay on the HASU; palliative care by discharge; activity of daily living (ADL) support, and new discharge to care home. In patients with more moderate stroke (NIHSS score of 5-15) the same outcomes were identified; being at greater risk for patients with UI, except for palliative care by discharge and ADL support. With the highest stroke severity group (NIHSS score of 16-48) all outcomes were identified except in-patient mortality, pneumonia, and ADL support. However, odds ratios diminished as NIHSS scores increased.
CONCLUSIONS: Urinary incontinence is a useful indicator of poor short-term outcomes in older patients with an acute stroke, but irrespective of stroke severity. This provides valuable information to healthcare professionals to identify at-risk individuals.
A hydrosol preparation system includes a conveyance unit, a distillation unit, a sterilization unit, and a filling unit. The conveyance unit is for conveying a container. The distillation unit performs distillation on a raw material to produce a crude hydrosol. The sterilization unit performs sterilization on the crude hydrosol to produce a final hydrosol. The filling unit fills the final hydrosol into the container. The preparation system integrates all procedures required by manufacturing of the hydrosol product so as to eliminate the need of transferring the semifinished hydrosol product among different production sites, thereby minimizing the risk of inclusion of impurities and maximizing safety and storability of the finished hydrosol product.
This multicenter study will be conducted in 2 cohorts (Cohort 1 and 2). Cohort transition will be determined by the Safety Review Team (SRT) before the start of Cohort 2.

For each cohort, the target number of subjects completing the treatment period is defined as 8 for SEP-363856 group and 4 for placebo group. Subjects will be randomly assigned to either group. Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. In the placebo group, placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
A nutraceutical gummy composition is disclosed for counteracting effects of alcohol-containing beverages and solid food products. The composition includes electrolytes, vitamin B complexes, and liver detoxification compounds. Specific components include ampelopsis grossedentata extract (DHM), prickly pear cactus extract, milk thistle extract, ginger root extract, and L-alanyl-L-glutamine. The composition also includes a gummy base and a coating, with the base comprising citrus pectin and water, and the coating comprising safflower oil and carnauba wax. The L-alanyl-L-glutamine component is particularly effective in reducing a glutamine rebound in a user. The composition is designed to be consumed by a subject to treat effects of alcohol consumption.
Risk Summary

Voriconazole can cause fetal harm when administered to a pregnant woman. There are no available data on the use of voriconazole in pregnant women. In animal reproduction studies, oral voriconazole was associated with fetal malformations in rats and fetal toxicity in rabbits. Cleft palates and hydronephrosis/hydroureter were observed in rat pups exposed to voriconazole during organogenesis at and above 10 mg/kg (0.3 times the RMD of 200 mg every 12 hours based on body surface area comparisons). In rabbits, embryomortality, reduced fetal weight and increased incidence of skeletal variations, cervical ribs and extrasternal ossification sites were observed in pups when pregnant rabbits were orally dosed at 100 mg/kg (6 times the RMD based on body surface area comparisons) during organogenesis. Rats exposed to voriconazole from implantation to weaning experienced increased gestational length and dystocia, which were associated with increased perinatal pup mortality at the 10 mg/kg dose [see Data]. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, inform the patient of the potential hazard to the fetus [see Warnings and Precautions (5.9)].

The background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively.

Data

Animal Data

Voriconazole was administered orally to pregnant rats during organogenesis (gestation days 6-17) at 10, 30, and 60 mg/kg/day. Voriconazole was associated with increased incidences of the malformations hydroureter and hydronephrosis at 10 mg/kg/day or greater, approximately 0.3 times the recommended human dose (RMD) based on body surface area comparisons, and cleft palate at 60 mg/kg, approximately 2 times the RMD based on body surface area comparisons. Reduced ossification of sacral and caudal vertebrae, skull, pubic, and hyoid bone, supernumerary ribs, anomalies of the sternebrae, and dilatation of the ureter/renal pelvis were also observed at doses of 10 mg/kg or greater. There was no evidence of maternal toxicity at any dose.

Voriconazole was administered orally to pregnant rabbits during the period of organogenesis (gestation days 7-19) at 10, 40, and 100 mg/kg/day. Voriconazole was associated with increased post-implantation loss and decreased fetal body weight, in association with maternal toxicity (decreased body weight gain and food consumption) at 100 mg/kg/day (6 times the RMD based on body surface area comparisons). Fetal skeletal variations (increases in the incidence of cervical rib and extra sternebral ossification sites) were observed at 100 mg/kg/day.

In a peri- and postnatal toxicity study in rats, voriconazole was administered orally to female rats from implantation through the end of lactation at 1, 3, and 10 mg/kg/day. Voriconazole prolonged the duration of gestation and labor and produced dystocia with related increases in maternal mortality and decreases in perinatal survival of F1 pups at 10 mg/kg/day, approximately 0.3 times the RMD.
Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR). We observed a higher frequency of cytotoxic CD8+ effector and gamma delta (γδ) T cells in CR vs REL samples. Pseudotime and gene regulatory network analyses revealed that CR CD8+ T cells were more advanced in maturation and had a stronger cytotoxicity signature, whereas REL samples were characterized by inflammatory tumor necrosis factor/NF-κB signaling and an immunosuppressive milieu. We identified ADGRG1/GPR56 as a surface marker enriched in CR CD8+ T cells and confirmed in a CD33-directed chimeric antigen receptor T cell/AML coculture model that GPR56 becomes upregulated on T cells upon antigen encounter and elimination of AML cells. We show that GPR56 continuously increases at the protein level on CD8+ T cells after allo-HCT and confirm faster interferon gamma (IFN-γ) secretion upon re-exposure to matched, but not unmatched, recipient AML cells in the GPR56+ vs GPR56- CD8+ T-cell fraction. Together, our data provide a single-cell reference map of BM-derived T cells after allo-HCT and propose GPR56 expression dynamics as a surrogate for antigen encounter after allo-HCT.
Although life expectancies have improved in the SCI population, longevity remains below the general population, due to increased incidence of cardiovascular disease, which is the leading cause of mortality in individuals with chronic SCI. Autonomic nervous system dysfunction and blood pressure instability contribute to the increased cardiovascular disease risk in the SCI population; however, because a majority of individuals with SCI remain asymptomatic the diagnosis and treatment of blood pressure instability is not a clinical priority. This is due, in part, to lack of safe and effective interventions, even though mounting evidence strongly supports adverse effects of blood pressure instability on the cerebral circulation, cognitive function, and quality of life. Identifying individualized transcutaneous stimulation parameters that safely and effectively increase and stabilize blood pressure in hypotensive individuals with SCI will provide the foundational evidence to support eventual wide-spread clinical utility throughout the VA healthcare system. 10 participants who are cleared, will go through multiple mapping sessions to find out the most appropriate electrode placement to increase blood pressure and then will perform an orthostatic provocation on a tilt table during stimulation to determine differences with stim and without. The study will take approximately 1 to 13 study visits, of between 3-5 hours, per participant.
The following dose equivalency scheme should generally provide equivalent exposure in pediatric and adult patients:

Experience with fluconazole in neonates is limited to pharmacokinetic studies in premature newborns. (See CLINICAL PHARMACOLOGY.) Based on the prolonged half-life seen in premature newborns (gestational age 26 to 29 weeks), these children, in the first two weeks of life, should receive the same dosage (mg/kg) as in older children, but administered every 72 hours. After the first two weeks, these children should be dosed once daily. No information regarding fluconazole pharmacokinetics in full-term newborns is available. 

Oropharyngeal candidiasis: The recommended dosage of fluconazole for oropharyngeal candidiasis in children is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Treatment should be administered for at least 2 weeks to decrease the likelihood of relapse. 

Esophageal candidiasis: For the treatment of esophageal candidiasis, the recommended dosage of fluconazole in children is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Doses up to 12 mg/kg/day may be used, based on medical judgment of the patient’s response to therapy. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms. 

Systemic Candida infections: For the treatment of candidemia and disseminated Candida infections, daily doses of 6 to 12 mg/kg/day have been used in an open, noncomparative study of a small number of children. 

Cryptococcal meningitis: For the treatment of acute cryptococcal meningitis, the recommended dosage is 12 mg/kg on the first day, followed by 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient’s response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in children with AIDS, the recommended dose of fluconazole is 6 mg/kg once daily.
The Proteus effect, which occurs when using an avatar in virtual reality, influences user behavior, changes attitudes, and improves physical performance. Here, we show that human pain perception can be alleviated by the Proteus effect. To investigate the pain alleviation effect of using an avatar in a virtual environment, we conducted two experiments using a head-mounted display and a thermal pain stimulator to induce acute pain. The first experiment involved 20 adult participants, while the second experiment involved 44 adult participants. Experimental results show that participants reported significantly lower pain scores (15.982% reduction), as measured by the Pain Assessment Scale (PAS), when using a muscular avatar than when using a normal avatar. The experiments also revealed several significant gender factors. For example, participants reported significantly lower pain scores when using a gender-congruent avatar. In addition, the use of a muscular avatar was particularly effective for male participants. In contrast, female participants consistently reported lower pain scores when using the avatar regardless of its body type (muscular/normal). To further our understanding, we also measured participants' gender-related pain stereotypes using the Gender Role Expectations of Pain (GREP) questionnaire, as well as participants' sense of embodiment. The results of these questionnaires are consistent with the results of the PAS, suggesting possible relationships between stereotypes and the Proteus effect on pain perception, and between the degree of immersion in an avatar and the user's perception of pain.
<P>PROBLEM TO BE SOLVED: To provide a hypoxia stress response promoter, to provide a method for screening the promoter, and to provide a method for screening an oxidative stress response promoter.  <P>SOLUTION: AGK2 ä2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide} is used as the hypoxia stress response promoter. Furthermore, the hypoxia stress response promoter is screened by measuring the activity of SIRT2 (a protein called also Sirtuin 2) in the presence of a test substance, and selecting a substance inhibiting the activity of the SIRT2. The test substance is further added into eEF1BδL gene, and a cell expressing a reporter gene linked to eEF1BδL target gene or an expression regulatory sequence of the target gene to measure the expression level of the target gene or reporter gene, and select a substance increasing the expression level. Thereby, the oxidative stress response promoter is screened.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The pilot trial will enroll patients who are coming in to see a valve specialist (cardiac surgeon or interventional cardiologist) to discuss treatment options for aortic stenosis. The study will recruit patients at Massachusetts General Hospital or at the University of Colorado Health Heart and Vascular Center, Anschutz Medical in Denver, Colorado and randomly assign them to usual care arm or decision aid arm. The decision aid will be given to the participant in clinic at the time of their appointment. Patient participants in both arms will be asked to complete a short survey after the visit. The survey will assess knowledge, treatment preference, shared decision making (SDM), and decisional conflict. Analyses will compare the two arms on these outcomes to generate preliminary data on impact of the intervention.
The invention discloses a traditional Chinese medicine pill for colonic ulcer suppository, which comprises the following components: the traditional Chinese medicine composition is prepared from 9 traditional Chinese medicines of coptis chinensis, white paeony root, divaricate saposhnikovia root, Chinese gall, largehead atractylodes rhizome, hairyvein agrimonia herb and bud, alum, tangerine peel, danshen root and the like, has the effects of cooling blood and stopping bleeding, balancing cold and heat, clearing away heat and toxic materials, eliminating desire to stop dysentery, regulating the middle warmer and relieving pain, purging the liver and tonifying the spleen, promoting blood circulation and removing blood stasis, astringing and stopping bleeding, promoting vital function and removing necrotic tissue, restoring intestinal mucosa, repairing ulcer surfaces, inhibiting microthrombosis, reducing blood viscosity, improving microcirculation and. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating physiological function, cooling blood, stopping bleeding, regulating chills and fever, clearing away heat and toxic materials, astringing, stopping dysentery, regulating the middle warmer, relieving pain, purging liver, invigorating spleen, promoting blood circulation, dispelling blood stasis, promoting granulation, improving microcirculation and blood supply of intestinal mucosa, and promoting healing of ulcer. 4. Can repair the clinical signs of patients and ulcerative colitis and relieve recovery patients.
PROBLEM TO BE SOLVED: To provide a liquid makeup cosmetic composed of a pigment, water and a poly-N-vinylcarboxylic acid amide, usable by filling in a cosmetic- containing applicator, resistant to precipitation and segregation over a long period and forming little spots on the skin. SOLUTION: The objective cosmetic is composed of at least (A) a pigment, (B) water and (C) a poly-N-vinylcarboxylic acid amide. The component A is e.g. Red 202 for an organic pigment and its content in the total ink is preferably 0.3-40 wt.%. The component A may be dispersed with a dispersing agent in the case of forming a cosmetic. The dispersing agent is a surfactant, a resin, etc., and the amount is preferably 0.2-20 pts.wt. based on 10 pts.wt. of the pigment. The component C is e.g. poly-N-vinylformamide and the amount is preferably 0.05-10 wt.%. A water-soluble organic solvent can be used in the cosmetic and the amount of the solvent is preferably 5-40 wt.% based on the total ink.
An exogenous stimulus is applied to tissues or cells which are at risk in a subsequent surgical procedure or other intervention which induces a response by the cells that minimizes reaction to the subsequent procedure. Stimuli can be chemical, physiological or physical. Examples include those stimuli known to induce expression of stress response proteins or heat shock proteins, especially heat shock protein 70 (hsp 70) and hsp 90, for example, exposure to heat or dilute hydrogen peroxide, or direct administration of exogenous heat shock proteins, or those stimuli which act to inhibit or reduce heat shock protein expression, for example, treatment with flavonoids. An amount effective to modulate levels of stress response proteins or reduce the endogenous response is administered, based on in vitro assays which are used to determine levels of heat shock proteins or which are experimentally determined to reduce cell proliferation, thrombus formation, and matrix deposition following subsequent exposure to a procedure. Procedures can be surgery, angioplasty, or abrasion. The method and compositions are also useful in mediating some disease processes, where the process involves undesirable migration.
The invention belongs to the field of research of a streptococcus suis prevention and control technology, and provides a pVAX-PTX3 eukaryotic expression vector, a constructing method and an antibacterial application of PTX protein expressed by the eukaryotic expression vector in streptococcus suis 2. The gene ptx3 sequence of the PTX3 protein in the recombinant eukaryotic expression vector pVAX-PTX3 is as shown in SEQ ID NO. 1, and the PTX3 protein can be stably expressed in a tissue body. The sequence of the PTX3 is as shown in SEQ ID NO. 2, and the PTX3 protein can be used for preparing a biological preparation for preventing or treating streptococcus suis disease caused by streptococcus suis 2. A pVAX-PTX3 recombinant plasmid is strong in stability and can be stably and effectively expressed in the tissue body, and the PTX3 generated from expression has an antibacterial effect on the streptococcus suis 2; upon in vitro tests, in vivo tests on BALB/c mice and piglets verify that the PTX3 protein expressed by the pVAX-PTX3 has an antibacterial effect on the streptococcus suis 2; and by virtue of the pVAX-PTX3, a novel method for the clinical prevention and treatment of the streptococcus suis disease is established.
The invention relates to a process for preserving plant extracts, plant juices, fruits and vegetables. The freshly produced juice or, in the case of fruits or vegetables, the liquid to be preserved is, depending on the plant species, mixed with about 10 to 20% of vinegar. This mixture is vigorously beaten for about one hour in an open vessel. Sugar or honey can be added to the extract for flavour enhancement. The extracts produced can also be used for pharmaceutical products. In addition, homeopathic dilutions can be prepared and preserved by this process.